At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 246 enrolled / 246 target
Drug / intervention
Sumatriptan +1 moredrug
Likely dose
Sumatriptan 6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label Evaluation of Treatment Satisfaction, Tolerability, Safety and Preference for Sumavel DosePro for Treatment of Migraine in Subjects Currently Treated With Triptans
In Brief
A Phase 4 clinical trial evaluating Sumavel DosePro and Sumatriptan for Migraine. Completed, enrolled 246 participants across 21 sites.
Signals
Enrolling slower than its timeline implies
Detailed Summary
The purpose of the study is to evaluate the treatment satisfaction of subjects using Sumavel DosePro to treat their moderate to severe migraines.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
CollaboratorsSynteract, Inc.
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2009
Enrollment StartNov 2009
Primary CompletionApr 2010
TodayJul 2026
First PostedNov 20, 2009
Enrollment StartNov 30, 2009
Primary CompletionApr 30, 2010
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 16.6 years ago
Arms & Interventions
Sumavel(R) DosePro(R)other
Single arm study (Sumavel DosePro)
Device: Sumavel DoseProDrug: Sumatriptan
Interventions
Sumavel DoseProdevice
Needle free delivery system containing 0.5 mL of solution of 6 mg sumatriptan, subcutaneous administration
Sumatriptandrug
subcutaneous injection, 6 mg, per migraine attack, no more than two administrations within a 24 hr period